ADDYI

LOE Approaching

flibanserin

Sprout Pharmaceuticals
NDAORALTABLET
Approved
Aug 2015
Lifecycle
LOE Approaching
Competitive Pressure
15/100

Mechanism of Action

P-Glycoprotein Inhibitors

Indications (8)

women less than 65 years of age with acquiredgeneralized hypoactive sexual desire disorder (HSDD)interpersonal difficultypsychiatric condition• Problems within the relationship• The effects of a medicationother drug substancemen • ADDYI is not indicated to enhance sexual performance

Loss of Exclusivity

LOE Date
May 9, 2028
26 months away
Patent Expiry
May 9, 2028
Exclusivity Expiry
Dec 13, 2028

Patent Records (1)

Patent #ExpiryTypeUse Code
7151103
May 9, 2028
U-1734
Company
Sprout Pharmaceuticals
Sprout Pharmaceuticals
NC - Raleigh
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers